What Functions Do These Features Confer To The Receptor? @mansoor_steven @OHSUNews #P2X7receptor

What Functions Do These Features Confer To The Receptor? @mansoor_steven @OHSUNews #P2X7receptor

OHSU

1 month
10 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Steven Mansoor, MD @mansoor_steven of @OHSUSOM answers common questions involving a protein associated with many disease is visualized for the first time.

__________

New drugs can be motivated by understanding how receptors of P2X7 proteins function. 

Scientists first noticed how a protein associated with various health issues functions at the molecular level.

The breakthrough, that one day could inspire new drugs to treat inflammation, coronary artery disease, leukemia, multiple sclerosis, and more, has been published today in the Cell journal.

Research assistant at Oregon Health & Science University Alanna McCarthy, B.S., and scientist at OHSU Steven Mansoor, M.D., Ph.D., used cryoelectron microscopy to obtain a protein receptor's 3D structure and observe its inner working. The protein receptor they studied is a protein of the cell membrane that enables electrically charged particles of sodium and calcium to enter and cause changes in a cell.

They specifically studied the P2X7 receptor, a subtype associated with inflammation of the ligand-gated ion channel P2X family, plaque buildup in arteries, metastasis of cancer, neurological conditions, and more.

P2X7 is unique because its channel remains open indefinitely once it is activated, allowing continuously charged particles to enter a cell and initiate the inflammation signaling pathways, ultimately resulting in cell death. These signaling activity may contribute to the receptor-related long list of ailments.

Unlike previous efforts to image the P2X7 receptor, they were able to capture the protein receptor in its entirety through the cryo-EM imaging approach of the team.

This helped them to imagine the receptor sections inside the cell that were sitting. As a result, they can specifically analyze how fatty acid molecules called palmitoyl groups change these parts. When these groups were eliminated by Mansoor and his colleagues, they found that the receptor was no longer open indefinitely, shutting down their ability to trigger signaling. He also found suddenly that a guanosine nucleotide inside the cell was bound to P2X7.

Read here: https://www.oncologytube.com/video/first-fully-visualized-protein-associated-with-many-diseases

Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
2 Views
Cancer-News 1 day
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
26 Views
Cancer-News 2 days
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 2 days
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
10 Views
kidneycancer 2 days
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 2 days
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
4 Views
kidneycancer 3 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
5 Views
Cancer-News 3 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 3 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
10 Views
kidneycancer 3 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
3 Views
Cancer-News 4 days